What is the approximate market price of a box of filgotinib?

Filgotinib (Filgotinib) is an oral selective JAK1 inhibitor jointly developed by the Belgian company Galapagos and the American Gilead Sciences, with the trade name Jyseleca. This drug has been launched in Europe, Japan and other places, and is mainly used to treat patients with moderate to severe rheumatoid arthritis and some inflammatory bowel diseases. Due to its precise efficacy and low side effects, it has attracted the attention of rheumatology and immunologists around the world in recent years.

Currently, the original drug of filgotinib has not yet been launched in mainland China, so it has not yet been included in the medical insurance system, and the domestic market price is not yet clear. However, from the perspective of overseas drug pricing, the price of the original version of filgotinib (specification200mg*30 tablets) sold in the EU is generally around RMB 10,000. Drug prices mainly depend on each country's medical system and exchange rate changes, so there are certain differences in selling prices in different regions. In European and American pharmacies, they are generally sold through prescription channels, and the price includes the pharmaceutical company's brand and regulatory certification costs, so the overall price of original drugs is relatively high.

In addition to the original drug, generic versions of filgotinib have been launched in some overseas countries, such as Laos. These drugs are consistent with the original research in terms of ingredients, dosage and mechanism of action, and also use Filgotinib as the main active ingredient. For example, the 100mg*30 tablets produced by Lucius Pharmaceutical Factory in Laos are priced at more than 900 yuan. The price is significantly lower than the original drug, and it is favored by some patients. It should be noted that these generic drugs should be purchased through formal channels to ensure reliable sources and safe ingredients to avoid counterfeit or inferior drugs affecting the therapeutic effect.

The market price of filgotinib still has room for downward adjustment in the future. As they are approved for marketing in more countries and the patent period gradually expires, the supply of generic drugs will increase, further reducing drug prices. At the same time, if registration and approval are completed in mainland China and included in medical insurance, patient accessibility will be greatly improved.

Reference materials:https://go.drugbank.com/drugs/DB14845